Follicular Lymphoma (FL) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030


 Follicular lymphoma (FL), commonly referred to as indolent lymphoma, is the second most common type of non-Hodgkin lymphoma (NHL). Advanced stage disease is considered incurable and is characterized by a prolonged relapsing/remitting course. A significant minority have less favorable outcomes, particularly those with transformed or early progressive disease. The introduction of anti-CD20 monoclonal antibodies (mAb) such as rituximab, and, more recently the type II anti-CD20 mAb, obinutuzumab, have revolutionized the management of FL and it is likely that anti-CD20 antibodies will remain at the forefront of the FL treatment armamentarium. But more recent insights demonstrating the intricate relationship between the FL tumor cell and its distinct immune microenvironment have led to a rapid accumulation of novel and innovative targeted therapies that harness the power of the immune system to attack the malignant cell.

FL affects approximately 3.7 in 10,000 individuals in the European Union (EU), which is below the EU threshold for orphan designation of 5 in 10,000 individuals

The overall 10-year prevalence of FL 25.2/100,000 population, with a higher prevalence in females than males (prevalence 26.2 vs. 24.1/100,000, respectively)

The competitive landscape of Follicular Lymphoma (FL) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Follicular Lymphoma (FL) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Follicular Lymphoma (FL) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Follicular Lymphoma (FL) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Rituximab Biosimilar (DRL_RI)   Dr. Reddy's Laboratories Limited            Phase 3

2          Obinutuzumab  Hoffmann-La Roche      Phase 1

3          Tazemetostat    Epizyme, Inc.    Phase 2

4          Loncastuximab Tesirine ADC Therapeutics S.A.  Phase 2

5          Duvelisib           CSPC ZhongQi Pharmaceutical Technology Co., Ltd.      Phase 2

6          Abexinostat       Xynomic Pharmaceuticals, Inc.  Phase 2

7          Idelalisib           Gilead Sciences            Phase 3

8          CHO-H01          Cho Pharma Inc.           Phase 1

9          ibrutinib Pharmacyclics LLC.       Phase 3

10        HMPL-689        Hutchison Medipharma Limited  Phase 2

Continued

Comments

Post a Comment

Popular posts from this blog

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more